1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.
Ahmed, S., Ayscough, A., Barker, G.R., Canning, H.E., Davenport, R., Downham, R., Harrison, D., Jenkins, K., Kinsella, N., Livermore, D.G., Wright, S., Ivetac, A.D., Skene, R., Wilkens, S.J., Webster, N.A., Hendrick, A.G.(2017) J Med Chem 60: 5663-5672
- PubMed: 28594552 
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00352
- Primary Citation of Related Structures:  
5V18, 5V1B - PubMed Abstract: 
Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe 2+ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.
Organizational Affiliation: 
Department of Computational Sciences and Crystallography, Takeda California Inc. , 10410 Science Center Dr., San Diego, California 92121, United States.